Gilead Sciences, Inc.
GILD NASDAQThere isn't enough steady cash-flow history to value Gilead Sciences yet. Analysts' mean target is about 4% higher.
No single event this week: analyst targets span ~₹12.1K–18.5K a share.
On consensus GILD is the cheapest of its peers, at ~16.5x next year's earnings. Otto can't build a cash-flow range for this one yet, so the range shown is the analysts' own; the price, ₹15.5K, sits inside it.
01 · Forward P/E
- GILD ~16.5x
- ABBV ~18.1x
- JNJ ~24x
- LLY ~28x
Next fiscal year's consensus earnings.
02 · Latest event
No results, sharp move or standout headline in the last week.
03 · The range, a share
- Analyst targets ~₹12.1K–18.5K
Current price ₹15.5K.
- ~16.5x
- Forward P/E, consensus
- ₹15.5K
- Price: inside the target range
- ~₹12.1K–18.5K
- Analyst target range
Forward P/E and analyst targets: Yahoo Finance consensus. No cash-flow range: the company's reported cash flows don't support one yet. Not investment advice — Otto just crunches numbers.
Price trend
+38221.4% over all saved history · S&P 500 +1552.7%
What think
The market's move: +38221.4% over the past year
Trading 85% up its 52-week range. Price is the market's live vote — not advice.
Analyst consensus: Buy · 26 analysts
Average 12-month target ₹16,195.86 — +4.3% vs today.
Yahoo Finance's analyst aggregate. Sentiment, not advice.
Insiders: 0 buys · 0 sales in recent filings
Open-market trades from SEC Form 4. Sales are often pre-planned (10b5-1); buys tend to say more. Sentiment, not advice.
InvestRight readers: 0 watching
This site's own activity — not a broad measure. Sentiment, not advice.
Otto's still crunching Gilead's numbers.
Select Refresh at the top of this page to pull the full statements now — it takes a few seconds.
Ownership & insiders
from SEC Form 4 filingsNo insider filings saved yet — Otto checks EDGAR on each refresh.
What does this show?
Buys and sells by the company's own directors and officers, from their SEC filings. Insiders sell for many reasons, but clusters of open-market buying can signal confidence.
Learn more on Investopedia →Spot a missing competitor? Sign in to add it — it'll show for everyone.
What does this show?
A few peers in the same business, each with its own mini snowflake, so you can see how this company stacks up rather than judging it in isolation. Anyone signed in can add a missing competitor — it shows for everyone, marked as user-added.
Learn more on Investopedia →In the news
- GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loom
- How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade
- Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
- What Just Happened To Alnylam Stock?
- Gilead's HIV Franchise Supports Growth Outlook, RBC Says
- Gilead (GILD) Q3 2026 Earnings Call Transcript
- GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth
- UBS Adjusts Gilead Sciences Price Target to $195 From $175, Maintains Buy Rating
My notes
Sign in to keep a private decision journal on this stock — only you can see your notes.
Hi! I can explain Gilead's numbers — valuation, health, the dividend, the fair-value gap. What would you like to know?
Otto explains what's on this page — not investment advice.